Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors

Costantine Albany, N. Adra, A. C. Snavely, K. Clinton Cary, Timothy Masterson, Richard Foster, Kenneth Kesler, Thomas Ulbright, Liang Cheng, M. Chovanec, F. Taza, K. Ku, M. J. Brames, Nasser Hanna, Lawrence Einhorn

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background: To report our experience utilizing a multidisciplinary clinic (MDC) at Indiana University (IU) since the publication of the International Germ Cell Cancer Collaborative Group (IGCCCG), and to compare our overall survival (OS) to that of the National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) Program. Patients and methods: We conducted a retrospective analysis of all patients with metastatic germ-cell tumor (GCT) seen at IU from 1998 to 2014. A total of 1611 consecutive patients were identified, of whom 704 patients received an initial evaluation by our MDC (including medical oncology, pathology, urology and thoracic surgery) and started first-line chemotherapy at IU. These 704 patients were eligible for analysis. All patients in this cohort were treated with cisplatin-etoposide-based combination chemotherapy. We compared the progression-free survival (PFS) and OS of patients treated at IU with that of the published IGCCCG cohort. OS of the IU testis cancer primary cohort (n=622) was further compared with the SEER data of 1283 patients labeled with 'distant' disease. The Kaplan-Meier method was used to estimate PFS and OS. Results: With a median follow-up of 4.4 years, patients with good, intermediate, and poor risk disease by IGCCCG criteria treated at IU had 5-year PFS of 90%, 84%, and 54% and 5-year OS of 97%, 92%, and 73%, respectively. The 5-year PFS for all patients in the IU cohort was 79% [95% confidence interval (CI) 76% to 82%]. The 5-year OS for the IU cohort was 90% (95% CI 87% to 92%). IU testis cohort had 5-year OS 94% (95% CI 91% to 96%) versus 75% (95% CI 73% to 78%) for the SEER 'distant' cohort between 2000 and 2014, P-value<0.0001. Conclusion: The MDC approach to GCT at high-volume cancer center associated with improved OS outcomes in this contemporary dataset. OS is significantly higher in the IU cohort compared with the IGCCCG and SEER 'distant' cohort.

Original languageEnglish (US)
Pages (from-to)341-346
Number of pages6
JournalAnnals of Oncology
Volume29
Issue number2
DOIs
StatePublished - Feb 1 2018

Fingerprint

Germ Cell and Embryonal Neoplasms
Survival
Disease-Free Survival
Confidence Intervals
Epidemiology
SEER Program
Medical Oncology
National Cancer Institute (U.S.)
Testicular Neoplasms
Urology
Etoposide
Combination Drug Therapy
Cisplatin
Thoracic Surgery
Publications
Testis
Pathology
Drug Therapy

Keywords

  • Germ-cell tumor
  • IGCCCG
  • Multidisciplinary
  • SEER
  • Testicular cancer

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this

Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors. / Albany, Costantine; Adra, N.; Snavely, A. C.; Cary, K. Clinton; Masterson, Timothy; Foster, Richard; Kesler, Kenneth; Ulbright, Thomas; Cheng, Liang; Chovanec, M.; Taza, F.; Ku, K.; Brames, M. J.; Hanna, Nasser; Einhorn, Lawrence.

In: Annals of Oncology, Vol. 29, No. 2, 01.02.2018, p. 341-346.

Research output: Contribution to journalArticle

@article{c741be735a0744639eec29f4835bd44e,
title = "Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors",
abstract = "Background: To report our experience utilizing a multidisciplinary clinic (MDC) at Indiana University (IU) since the publication of the International Germ Cell Cancer Collaborative Group (IGCCCG), and to compare our overall survival (OS) to that of the National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) Program. Patients and methods: We conducted a retrospective analysis of all patients with metastatic germ-cell tumor (GCT) seen at IU from 1998 to 2014. A total of 1611 consecutive patients were identified, of whom 704 patients received an initial evaluation by our MDC (including medical oncology, pathology, urology and thoracic surgery) and started first-line chemotherapy at IU. These 704 patients were eligible for analysis. All patients in this cohort were treated with cisplatin-etoposide-based combination chemotherapy. We compared the progression-free survival (PFS) and OS of patients treated at IU with that of the published IGCCCG cohort. OS of the IU testis cancer primary cohort (n=622) was further compared with the SEER data of 1283 patients labeled with 'distant' disease. The Kaplan-Meier method was used to estimate PFS and OS. Results: With a median follow-up of 4.4 years, patients with good, intermediate, and poor risk disease by IGCCCG criteria treated at IU had 5-year PFS of 90{\%}, 84{\%}, and 54{\%} and 5-year OS of 97{\%}, 92{\%}, and 73{\%}, respectively. The 5-year PFS for all patients in the IU cohort was 79{\%} [95{\%} confidence interval (CI) 76{\%} to 82{\%}]. The 5-year OS for the IU cohort was 90{\%} (95{\%} CI 87{\%} to 92{\%}). IU testis cohort had 5-year OS 94{\%} (95{\%} CI 91{\%} to 96{\%}) versus 75{\%} (95{\%} CI 73{\%} to 78{\%}) for the SEER 'distant' cohort between 2000 and 2014, P-value<0.0001. Conclusion: The MDC approach to GCT at high-volume cancer center associated with improved OS outcomes in this contemporary dataset. OS is significantly higher in the IU cohort compared with the IGCCCG and SEER 'distant' cohort.",
keywords = "Germ-cell tumor, IGCCCG, Multidisciplinary, SEER, Testicular cancer",
author = "Costantine Albany and N. Adra and Snavely, {A. C.} and Cary, {K. Clinton} and Timothy Masterson and Richard Foster and Kenneth Kesler and Thomas Ulbright and Liang Cheng and M. Chovanec and F. Taza and K. Ku and Brames, {M. J.} and Nasser Hanna and Lawrence Einhorn",
year = "2018",
month = "2",
day = "1",
doi = "10.1093/annonc/mdx731",
language = "English (US)",
volume = "29",
pages = "341--346",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Multidisciplinary clinic approach improves overall survival outcomes of patients with metastatic germ-cell tumors

AU - Albany, Costantine

AU - Adra, N.

AU - Snavely, A. C.

AU - Cary, K. Clinton

AU - Masterson, Timothy

AU - Foster, Richard

AU - Kesler, Kenneth

AU - Ulbright, Thomas

AU - Cheng, Liang

AU - Chovanec, M.

AU - Taza, F.

AU - Ku, K.

AU - Brames, M. J.

AU - Hanna, Nasser

AU - Einhorn, Lawrence

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Background: To report our experience utilizing a multidisciplinary clinic (MDC) at Indiana University (IU) since the publication of the International Germ Cell Cancer Collaborative Group (IGCCCG), and to compare our overall survival (OS) to that of the National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) Program. Patients and methods: We conducted a retrospective analysis of all patients with metastatic germ-cell tumor (GCT) seen at IU from 1998 to 2014. A total of 1611 consecutive patients were identified, of whom 704 patients received an initial evaluation by our MDC (including medical oncology, pathology, urology and thoracic surgery) and started first-line chemotherapy at IU. These 704 patients were eligible for analysis. All patients in this cohort were treated with cisplatin-etoposide-based combination chemotherapy. We compared the progression-free survival (PFS) and OS of patients treated at IU with that of the published IGCCCG cohort. OS of the IU testis cancer primary cohort (n=622) was further compared with the SEER data of 1283 patients labeled with 'distant' disease. The Kaplan-Meier method was used to estimate PFS and OS. Results: With a median follow-up of 4.4 years, patients with good, intermediate, and poor risk disease by IGCCCG criteria treated at IU had 5-year PFS of 90%, 84%, and 54% and 5-year OS of 97%, 92%, and 73%, respectively. The 5-year PFS for all patients in the IU cohort was 79% [95% confidence interval (CI) 76% to 82%]. The 5-year OS for the IU cohort was 90% (95% CI 87% to 92%). IU testis cohort had 5-year OS 94% (95% CI 91% to 96%) versus 75% (95% CI 73% to 78%) for the SEER 'distant' cohort between 2000 and 2014, P-value<0.0001. Conclusion: The MDC approach to GCT at high-volume cancer center associated with improved OS outcomes in this contemporary dataset. OS is significantly higher in the IU cohort compared with the IGCCCG and SEER 'distant' cohort.

AB - Background: To report our experience utilizing a multidisciplinary clinic (MDC) at Indiana University (IU) since the publication of the International Germ Cell Cancer Collaborative Group (IGCCCG), and to compare our overall survival (OS) to that of the National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) Program. Patients and methods: We conducted a retrospective analysis of all patients with metastatic germ-cell tumor (GCT) seen at IU from 1998 to 2014. A total of 1611 consecutive patients were identified, of whom 704 patients received an initial evaluation by our MDC (including medical oncology, pathology, urology and thoracic surgery) and started first-line chemotherapy at IU. These 704 patients were eligible for analysis. All patients in this cohort were treated with cisplatin-etoposide-based combination chemotherapy. We compared the progression-free survival (PFS) and OS of patients treated at IU with that of the published IGCCCG cohort. OS of the IU testis cancer primary cohort (n=622) was further compared with the SEER data of 1283 patients labeled with 'distant' disease. The Kaplan-Meier method was used to estimate PFS and OS. Results: With a median follow-up of 4.4 years, patients with good, intermediate, and poor risk disease by IGCCCG criteria treated at IU had 5-year PFS of 90%, 84%, and 54% and 5-year OS of 97%, 92%, and 73%, respectively. The 5-year PFS for all patients in the IU cohort was 79% [95% confidence interval (CI) 76% to 82%]. The 5-year OS for the IU cohort was 90% (95% CI 87% to 92%). IU testis cohort had 5-year OS 94% (95% CI 91% to 96%) versus 75% (95% CI 73% to 78%) for the SEER 'distant' cohort between 2000 and 2014, P-value<0.0001. Conclusion: The MDC approach to GCT at high-volume cancer center associated with improved OS outcomes in this contemporary dataset. OS is significantly higher in the IU cohort compared with the IGCCCG and SEER 'distant' cohort.

KW - Germ-cell tumor

KW - IGCCCG

KW - Multidisciplinary

KW - SEER

KW - Testicular cancer

UR - http://www.scopus.com/inward/record.url?scp=85042563418&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042563418&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdx731

DO - 10.1093/annonc/mdx731

M3 - Article

VL - 29

SP - 341

EP - 346

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 2

ER -